CSIMarket
 


Aytu Biopharma Inc   (AYTU)
Other Ticker:  
 
 

AYTU's Revenue Growth by Quarter and Year

Aytu Biopharma Inc 's Revenue results by quarter and year




AYTU Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter June - 29.97 27.45 23.48
III Quarter March - 22.73 24.20 13.48
II Quarter December 22.20 26.28 23.13 15.15
I Quarter September 21.78 27.66 21.90 13.52
FY   43.98 106.64 96.68 65.63



AYTU Revenue second quarter 2024 Y/Y Growth Comment
Aytu Biopharma Inc reported decline in Revenue in the second quarter 2024 by -15.51% to $ 22.20 millions, from the same quarter in 2023.
The contraction in the second quarter 2024 Aytu Biopharma Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 98.91%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue growth. While Aytu Biopharma Inc ' s Revenue fall of -15.51% ranks overall at the positon no. 993 in the second quarter 2024.




AYTU Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter June - 9.18 % 16.91 % 58.01 %
III Quarter March - -6.07 % 79.53 % 65.2 %
II Quarter December -15.51 % 13.62 % 52.67 % 376.42 %
I Quarter September -21.26 % 26.3 % 61.98 % 838.89 %
FY   - 10.3 % 47.31 % 137.45 %

Financial Statements
Aytu Biopharma Inc 's second quarter 2024 Revenue $ 22.20 millions AYTU's Income Statement
Aytu Biopharma Inc 's second quarter 2023 Revenue $ 26.28 millions Quarterly AYTU's Income Statement
New: More AYTU's historic Revenue Growth >>


AYTU Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter June - 31.85 % 13.43 % 74.18 %
III Quarter March - -13.51 % 4.63 % -11.02 %
II Quarter December 1.94 % -4.99 % 5.62 % 12.06 %
I Quarter September -27.33 % 0.77 % -6.73 % -9.02 %
FY (Year on Year)   - 10.3 % 47.31 % 137.45 %




Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #144
Overall #993

Revenue Y/Y Growth Statistics
High Average Low
493.49 % 98.91 % -8.43 %
(Dec 31 2020)   (Dec 31 2023)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #144
Overall #993
Revenue Y/Y Growth Statistics
High Average Low
493.49 % 98.91 % -8.43 %
(Dec 31 2020)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Aytu Biopharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
898.59 % 49.21 % -42.21 %
(Jun 30 2015)  


AYTU's II. Quarter Q/Q Revenue Comment
Aytu Biopharma Inc achieved in the II. Quarter 2024 below company average Revenue growth of 1.94% quarter on quarter, to $ 22.20 millions.

II. Quarter 2024 Aytu Biopharma Inc 's Revenue Q/Q growth were a mixed bag, although below the regular, yet it shows absolute improvement compare to the -4.99% in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Aytu Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 852.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #138
Overall #852
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #138
Overall #852
Revenue Q/Q Growth Statistics
High Average Low
898.59 % 49.21 % -42.21 %
(Jun 30 2015)  


AYTU's II. Quarter Q/Q Revenue Comment
Aytu Biopharma Inc achieved in the II. Quarter 2024 below company average Revenue growth of 1.94% quarter on quarter, to $ 22.20 millions.

Although the II. Quarter 2024 Aytu Biopharma Inc 's Revenue quarter on quarter growth was below the average of 49.21 %, that was still encouraging news, as the II. Quarter improvement, outshines the -4.99% rise in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Aytu Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 852.


Aytu Biopharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 96.69 $ 100.76 $ 106.63 $ 104.12 $ 105.58
Y / Y Revenue Growth (TTM) -8.43 % -1.63 % 10.31 % 12.31 % 28.78 %
Year on Year Revenue Growth Overall Ranking # 306 # 408 # 498 # 353 # 553
Seqeuential Revenue Change (TTM) -4.05 % -5.51 % 2.42 % -1.39 % 3.08 %
Seq. Revenue Growth (TTM) Overall Ranking # 1282 # 1476 # 2147 # 1316 # 1819




Cumulative Revenue growth Comment
Aytu Biopharma Inc 's cumulative 12 months Revenue continue to decline, but on the faster rate at -8.43% year on year, at Dec 31 2023 compare to the -1.63% decrease at Sep 30 2023. If the Aytu Biopharma Inc 's fiscal year would end at Dec 31 2023, annual Revenue would be $97 millions.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 306, from total ranking in previous quarter at 408.

Revenue TTM Q/Q Growth Statistics
High Average Low
493.49 %
98.91 %
-8.43 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 74
Overall # 306

Revenue TTM Y/Y Growth Statistics
High Average Low
493.49 %
98.91 %
-8.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 196
S&P 500 # 1282
Cumulative Revenue growth Comment
Aytu Biopharma Inc 's cumulative 12 months Revenue continue to decline, but on the faster rate at -8.43% year on year, at Dec 31 2023 compare to the -1.63% decrease at Sep 30 2023. If the Aytu Biopharma Inc 's fiscal year would end at Dec 31 2023, annual Revenue would be $97 millions.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 306, from total ranking in previous quarter at 408.

Revenue TTM Q/Q Growth Statistics
High Average Low
493.49 %
98.91 %
-8.43 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 74
Overall # 306

Revenue TTM Y/Y Growth Statistics
High Average Low
493.49 %
98.91 %
-8.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 196
S&P 500 # 1282




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AYTU's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for AYTU's Competitors
Revenue Growth for Aytu Biopharma Inc 's Suppliers
Revenue Growth for AYTU's Customers

You may also want to know
AYTU's Annual Growth Rates AYTU's Profitability Ratios AYTU's Asset Turnover Ratio AYTU's Dividend Growth
AYTU's Roe AYTU's Valuation Ratios AYTU's Financial Strength Ratios AYTU's Dividend Payout Ratio
AYTU's Roa AYTU's Inventory Turnover Ratio AYTU's Growth Rates AYTU's Dividend Comparisons



Companies with similar Revenue decline for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Hookipa Pharma inc -5.38%$ -5.378 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com